Similar articles

• Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.

  Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, Kováč P, Xu P, LaRocque RC, Calderwood SB, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB, Qadri F, Ryan ET. Islam K, et al. PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376. doi: 10.1371/journal.pntd.0006376. eCollection 2018 Apr. PLoS Negl Trop Dis. 2018. PMID: 29624592 Free PMC article. Clinical Trial.
• Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.

  Chowdhury MI, Sheikh A, Qadri F. Chowdhury MI, et al. Expert Rev Vaccines. 2009 Dec;8(12):1643-52. doi: 10.1586/erv.09.137. Expert Rev Vaccines. 2009. PMID: 19943759 Review.
• Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.

  Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F. Shamsuzzaman S, et al. Vaccine. 2009 Feb 25;27(9):1386-92. doi: 10.1016/j.vaccine.2008.12.041. Epub 2009 Jan 13. Vaccine. 2009. PMID: 19146897
• Questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003.

  Kabir S. Kabir S. Vaccine. 2007 Feb 9;25(8):1353-4. doi: 10.1016/j.vaccine.2006.09.057. Epub 2006 Oct 4. Vaccine. 2007. PMID: 17049687 Clinical Trial. No abstract available.
• A review of the current status of enteric vaccines.

  Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.